Current Clinical Trials and Vaccine Development Strategies for Corona Virus Disease (COVID-19)
Author(s) -
Abhi Bhadra,
Shweta Singh,
Shaswat Chandrakar,
Vanshika Kumar,
Sakshi Sankhla,
S. T,
Selvarajan Ethiraj
Publication year - 2020
Publication title -
journal of pure and applied microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.149
H-Index - 16
eISSN - 2581-690X
pISSN - 0973-7510
DOI - 10.22207/jpam.14.spl1.36
Subject(s) - hydroxychloroquine , lopinavir , medicine , ritonavir , clinical trial , intensive care medicine , azithromycin , covid-19 , vaccination , pandemic , lopinavir/ritonavir , disease , coronavirus , chloroquine , virology , immunology , virus , viral load , malaria , antiretroviral therapy , infectious disease (medical specialty) , biology , microbiology and biotechnology , antibiotics
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached global epidemic status claiming more than 319K lives and affecting more than 4.81M people and counting worldwide. Considering the severity of the situation and low recovery rate many research institutions and pharmaceutical industries are rushing to learn more about this new virus and the morbid physiology of this disease with effective diagnostic methods, therapeutic agents and vaccines. Various approaches are highlighted for comparing the possible treatment methods available for COVID-19 some of which are BCG vaccination on COVID-19 and Non-pharmaceutical interventions, drug based clinical trials of Hydroxychloroquine-Azithromycin, chloroquine, lopinavir/ritonavir, ChAdOx1 nCoV-19, Remdesivir, Stem Cell therapy and mesenchymal stromal cell therapy, etc.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom